Please login to the form below

Not currently logged in
Email:
Password:

MEDI4736

This page shows the latest MEDI4736 news and features for those working in and with pharma, biotech and healthcare.

AZ gets orphan status for selumetinib in thyroid cancer

AZ gets orphan status for selumetinib in thyroid cancer

immuno-oncology candidate durvalumab (MEDI4736).

Latest news

  • Roche and AZ claim FDA breakthrough status for new drugs Roche and AZ claim FDA breakthrough status for new drugs

    Meanwhile, AZ has revealed that the FDA granted breakthrough status for its PD-L1 inhibitor durvalumab (MEDI4736) for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder

  • AZ takes majority stake in cancer drug developer Acerta AZ takes majority stake in cancer drug developer Acerta

    AZ's agreement with Celgene, announced earlier this year, covers the development of its MEDI4736 checkpoint inhibitor for haematological malignancies including non-Hodgkin lymphoma (NHL), myelodysplastic syndromes and multiple myeloma.

  • AZ confirms interest in Acerta takeover AZ confirms interest in Acerta takeover

    If consummated, the deal with Acerta would be AZ's second in the haematological malignancy category this year, after it linked with Celgene to develop its MEDI4736 checkpoint inhibitor candidate for

  • AZ halts durvalumab combination trials on safety grounds AZ halts durvalumab combination trials on safety grounds

    Saysmove is a precautionary step after respiratory disease reports. AstraZeneca (AZ) has suspended two trials involving its PD-1 inhibitor durvalumab (MEDI4736) after reports of respiratory disease in some patients.

  • AZ and Peregrine join forces on cancer trial AZ and Peregrine join forces on cancer trial

    The two companies will look at the benefits of combining AZ's PD-L1 checkpoint inhibitor durvalumab (MEDI4736) with Peregrine's bavituximab, which targets a molecule called phosphatidylserine (PS) involved in

More from news
Approximately 5 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    AstraZeneca will collaborate with Peregrine on a non-exclusive basis looking at the combination of bavituximab and durvalumab [MEDI4736] in solid tumours.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Completing the deal haul is the exclusive collaboration around AZ's MEDI4736 for an upfront payment of $450m plus royalties. ... MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1).

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    485. AstraZeneca/Celgene. Exclusive collaboration. MEDI4736 - an investigational checkpoint inhibitor in serious blood cancers.

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... MEDI4736 blocks the signals that help tumours avoid detection by the immune system, countering the tumour's

  • Pharma deals during July 2014 Pharma deals during July 2014

    in multiple solid tumours. The focus of the study will be KHK's anti-CCR4 antibody, mogamulizumab, in combination with either AZ's anti-PD-L1 antibody, MEDI4736, or AZ's

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics